在 T 细胞急性淋巴细胞白血病中争分夺秒。
Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
机构信息
Department of Pediatrics, Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Department of Pathology, Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
出版信息
Clin Cancer Res. 2017 Feb 15;23(4):873-875. doi: 10.1158/1078-0432.CCR-16-2825. Epub 2016 Dec 22.
Abstract
CDK4/6 inhibition was synergistic with dexamethasone and everolimus but antagonistic with conventional chemotherapy in T-cell acute lymphoblastic leukemia (T-ALL) preclinical models. Cyclin-dependent kinase inhibition in combination with glucocorticoids and mTOR inhibition offers a unique therapeutic opportunity in T-ALL. .
摘要
CDK4/6 抑制与地塞米松和依维莫司协同作用，但与 T 细胞急性淋巴细胞白血病（T-ALL）临床前模型中的常规化疗拮抗。细胞周期蛋白依赖性激酶抑制与糖皮质激素和 mTOR 抑制联合提供了 T-ALL 独特的治疗机会。
Zotero 插件